Gangani Kishorbhai, Fong Hee K, Faisaluddin Mohammed, Lodhi Muhammad U, Manaktala Pritika, Sadolikar Ashish, Shah Vraj, Gandhi Zainab, Abu Hassan Falah, Savani Sejal, Doshi Rajkumar, Desai Rupak
Department of Internal Medicine Texas Health Arlington Memorial Hospital Arlington TX USA.
Division of Cardiovascular Medicine UC Davis Medical Center Sacramento CA USA.
J Arrhythm. 2020 Dec 18;37(1):121-127. doi: 10.1002/joa3.12482. eCollection 2021 Feb.
Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency associated with fatal complications including arrhythmia. The epidemiology and mortality outcomes of arrhythmia in TLS are scarcely studied in the literature.
We used the National Inpatient Sample (NIS) to study the prevalence and outcome of arrhythmia in patients hospitalized with TLS (ICD-9 code 277.88) from 2009 to 2014. Baseline characteristics, burden of arrhythmia, and pertinent outcomes were analyzed. Multivariable regression analysis was performed to identify the impact of underlying malignancy in predicting TLS-related mortality.
A total of 9034 cases of arrhythmia among 37 861 TLS patients were identified. More than half of the arrhythmia cases (67%) were found among white old (>65) males admitted to large bed size and urban teaching hospitals. Arrhythmic cohort showed higher frequency of comorbidities such as fluid-electrolyte disturbances, hypertension, congestive heart failure, renal failure, dyslipidemia, diabetes, pulmonary circulatory disorders, chronic pulmonary disease, coagulopathy, and deficiency anemia. The most common malignancies were leukemia, lymphoma, metastatic tumor, and solid tumor without metastasis. We found significantly higher odds of in-hospital mortality among patients with TLS compared to general inpatient population on unadjusted (OR 9.69, 95% CI: 9.27-10.13, < .001) and adjusted (OR 4.62, 95% CI: 4.39-4.85) multivariable analyses. Overall in-hospital mortality (32% vs 21.3%), median length of stay (11 days vs 9 days), and hospital charges were higher among arrhythmic than nonarrhythmic patients.
With the availability of more advanced cancer therapy in the US, nearly one in four inpatient encounters of TLS had arrhythmia. Arrhythmia in TLS patients was associated with higher odds of mortality and increased resource utilization. Therefore, strategies to improve the supportive care of TLS patients plus timely diagnosis and treatment of arrhythmia are of utmost importance in reducing mortality and health-care cost.
肿瘤溶解综合征(TLS)是一种危及生命的肿瘤急症,可引发包括心律失常在内的致命并发症。TLS中心律失常的流行病学及死亡率相关研究在文献中较为少见。
我们使用全国住院患者样本(NIS)研究2009年至2014年因TLS(国际疾病分类第九版代码277.88)住院患者中心律失常的患病率及转归情况。分析了基线特征、心律失常负担及相关转归。进行多变量回归分析以确定潜在恶性肿瘤对预测TLS相关死亡率的影响。
在37861例TLS患者中共识别出9034例心律失常病例。超过半数(67%)的心律失常病例见于入住大型床位及城市教学医院的65岁以上白人男性。心律失常队列中合并症如水电解质紊乱、高血压、充血性心力衰竭、肾衰竭、血脂异常、糖尿病、肺循环障碍、慢性肺病、凝血病及缺铁性贫血的发生频率更高。最常见的恶性肿瘤为白血病、淋巴瘤、转移性肿瘤及无转移的实体瘤。在未校正(比值比9.69,95%置信区间:9.27 - 10.13,P <.001)及校正(比值比4.62,95%置信区间:4.39 - 4.85)多变量分析中,我们发现TLS患者的院内死亡率显著高于普通住院患者人群。总体而言,心律失常患者的院内死亡率(32%对21.3%)、中位住院时间(11天对9天)及住院费用均高于无心律失常患者。
随着美国更先进癌症治疗方法的应用,近四分之一的TLS住院病例合并心律失常。TLS患者中的心律失常与更高的死亡几率及资源利用增加相关。因此,改善TLS患者支持治疗以及及时诊断和治疗心律失常的策略对于降低死亡率和医疗成本至关重要。